查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1454231

SPG50（痉挛性截瘫 50）的全球市场：依治疗类型、给药途径、最终使用者和地区

Global Spastic Paraplegia 50 Market, By Treatment Type, By Route of Administration, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3个工作天内

价格
简介目录

SPG50（痉挛性截瘫50）的全球市场规模预计2023年为1.3亿美元，2031年达到2.863亿美元，2024年至2031年复合年增长率为10.4%。

报告范围 报告详情
基准年 2023年 2023/2024年市场规模 1.3亿美元
实际资料 2019-2023 预测期 2024-2031
预测期2023/2024~2030/2031年复合成长率： 10.40% 2030/2031价值预测 2.863 亿美元
图 1. SPG50（痉挛性截瘫 50）的全球市场占有率（%），按地区划分，2024 年
全球痉挛性截瘫50个市场-IMG1

SPG50（痉挛性截瘫50）是一种罕见的遗传性神经系统疾病，其特征是下肢痉挛和无力。它是由 CYTH4 基因突变引起的，该基因编码 thylysin-4 蛋白，对于中枢神经系统轴突髓鞘形成至关重要。缺乏适当的髓鞘形成会影响大脑和下肢之间的运动神经讯号，导致僵硬和运动障碍。目前，尚无针对 SPG50 的核准治疗方法，但基因和细胞疗法的研究和开发有望在未来恢復髓鞘形成。

市场动态：.

SPG50（痉挛性截瘫 50）的全球市场受到罕见遗传病患病率上升、对罕见适应症的认识不断提高以及为开发新治疗方法活性化。然而，开发孤儿疾病药物的高成本是一项重大挑战。此外，监管核准时间长和病患数量少等市场限制也会影响该产品的商业性可行性。也就是说，政府以研究津贴、对药物开发商的税收优惠以及孤儿药等指定项目的形式增加支持，为该行业增加投资提供了机会。

本研究的主要特点

  • 本报告对SPG50（痉挛性截瘫50）的全球市场进行了详细分析，并列出了以2023年为基准年的预测期（2024-2031年）的市场规模和年复合成长率（CAGR%）。 。
  • 它还说明了各个细分市场的潜在商机，并为该市场提供了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
  • 它根据公司亮点、产品系列、主要亮点、绩效和策略等参数，介绍了全球 SPG50（痉挛性截瘫 50）市场的主要企业。
  • 该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • SPG50（痉挛性截瘫 50）的全球市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 透过用于分析全球 SPG50（痉挛性截瘫 50）市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章 市场动态、法规与趋势分析

  • 市场动态
  • 主要亮点
  • 监管场景
  • 最近的趋势
  • PEST分析
  • 波特的分析
  • 管道概览
  • 市场相关人员的投资场景
  • 合併、收购和合作

第四章全球 SPG50（痉挛性截瘫 50）市场 - 冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 经济影响

第5章全球SPG50（痉挛性截瘫50）市场，依治疗型，2019-2031

  • 药品
  • 物理治疗
  • 外科手术
  • 辅助设备
  • 其他的

第 6 章 全球 SPG50（痉挛性截瘫 50）市场，依给药途径，2019-2031 年

  • 口服
  • 注射
  • 外用
  • 其他的

第 7 章 全球 SPG50（痉挛性截瘫 50）市场，依最终使用者划分，2019-2031 年

  • 医院和诊所
  • 復健中心
  • 居家照护环境

第8章全球SPG50（痉挛性截瘫50）市场，依地区，2019-2031

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章 竞争格局

  • 公司简介
    • Pfizer
    • Sanofi
    • Novartis
    • GlaxoSmithKline
    • Johnson &Johnson
    • Merck
    • AstraZeneca
    • Bayer
    • Boehringer Ingelheim
    • Amgen
    • Biogen
    • Takeda Pharmaceutical
    • AbbVie
    • Bristol-Myers Squibb
    • Astellas Pharma
    • Daiichi Sankyo
    • Eisai
    • Eli Lilly
    • Gilead Sciences
    • Novo Nordisk

第10章

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6670

The global spastic paraplegia 50 market was valued at US$ 130 Mn in 2023 and is expected to reach US$ 286.3 Mn by 2031, growing at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 130 Mn
Historical Data for: 2019 to 2023 Forecast Period: 2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 10.40% 2030/2031 Value Projection: US$ 286.3 Mn
Figure 1. Global Spastic Paraplegia 50 Market Share (%), By Region, 2024
Global Spastic Paraplegia 50 Market - IMG1

Spastic Paraplegia 50 (SPG50) is a rare genetic neurological disorder characterized by lower limb spasticity and weakness. It is caused by mutations in the CYTH4 gene, which encodes the cylicin-4 protein essential for myelination of axons in the central nervous system. Lack of proper myelination affects motor nerve signals between the brain and lower limbs, resulting in stiffness and impaired mobility. Currently, there is no approved treatment for SPG50; however, research into the development of gene and cell therapies holds promise to restore myelination in the future.

Market Dynamics:

The global spastic paraplegia 50 market is driven by the rising prevalence of rare genetic disorders, growing awareness about orphan indications, and increasing research focus on developing novel treatments. However, the high costs associated with orphan drug development pose a major challenge. The market also faces restraints from long regulatory approval timelines and a small patient pool, affecting the commercial viability of products. Nonetheless, increasing government support in the form of research grants, tax incentives for drug developers, and designation programs such as orphan drug status present lucrative opportunities for greater investment in this space.

Key features of the study:

  • This report provides in-depth analysis of the global spastic paraplegia 50 market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global spastic paraplegia 50 market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer, Sanofi, Novartis, GlaxoSmithKline, Johnson & Johnson, Merck, AstraZeneca, Bayer, Boehringer Ingelheim, Amgen, Biogen, Takeda Pharmaceutical, AbbVie, Bristol-Myers Squibb, Astellas Pharma, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, and Novo Nordisk.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global spastic paraplegia 50 market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spastic paraplegia 50 market.

Detailed Segmentation:

  • Global Spastic Paraplegia 50 Market, By Treatment Type
    • Medication
    • Physiotherapy
    • Surgery
    • Assistive Devices
    • Others
  • Global Spastic Paraplegia 50 Market, By Route of Administration
    • Oral
    • Injectable
    • Topical
    • Others
  • Global Spastic Paraplegia 50 Market, By End User
    • Hospitals & Clinics
    • Rehab Centers
    • Home Care Settings
  • Global Spastic Paraplegia 50 Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Top Companies in the Global Spastic Paraplegia 50 Market:
    • Pfizer
    • Sanofi
    • Novartis
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck
    • AstraZeneca
    • Bayer
    • Boehringer Ingelheim
    • Amgen
    • Biogen
    • Takeda Pharmaceutical
    • AbbVie
    • Bristol-Myers Squibb
    • Astellas Pharma
    • Daiichi Sankyo
    • Eisai
    • Eli Lilly
    • Gilead Sciences
    • Novo Nordisk

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Spastic Paraplegia 50 Market, By Treatment Type
    • Spastic Paraplegia 50 Market, By Route Of Administration
    • Spastic Paraplegia 50 Market, By End User
    • Spastic Paraplegia 50 Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restrains
    • Opportunities
  • Key Highlights
  • Regulatory Scenario
  • Recent Trends
  • PEST Analysis
  • PORTER's Analysis
  • Pipeline Overview
  • Investment Scenario by Market Players
  • Mergers, Acquisitions, and Collaborations

4. Global Spastic Paraplegia 50 Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Economic Impact

5. Global Spastic Paraplegia 50 Market, By Treatment Type, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Medication
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Physiotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Surgery
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Assistive Devices
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

6. Global Spastic Paraplegia 50 Market, By Route Of Administration, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Spastic Paraplegia 50 Market, By End User, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Hospitals & Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Rehab Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
  • Home Care Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Spastic Paraplegia 50 Market, By Region, 2019-2031, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2019 -2031
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profile
    • Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Sanofi
    • Novartis
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck
    • AstraZeneca
    • Bayer
    • Boehringer Ingelheim
    • Amgen
    • Biogen
    • Takeda Pharmaceutical
    • AbbVie
    • Bristol-Myers Squibb
    • Astellas Pharma
    • Daiichi Sankyo
    • Eisai
    • Eli Lilly
    • Gilead Sciences
    • Novo Nordisk
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us